Effects of Methotrexate, Sulphasalazine and Aurothiomalate on Polymorphonuclear Leucocytes in Rheumatoid Arthritis

References

• Greenwald R A. Oxygen radicals, inflammation and arthritis: patophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991; 20: 219–40
   PubMed Web of Science ®Google Scholar
• Cencetti A, De-Martino M, Graziani E, Bongi S M, Palermo C, Pavari E, Zoppi M. Superoxide anion production by circulating polymorphonuclear leucocytes in rheumatoid arthritis. Clin Rheumatol 1990; 9: 51–5
   PubMedGoogle Scholar
• Al Balla S, Johnston C, Davis P. The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation. Clin Exp Rheumatol 1990; 8: 41–5
   PubMedGoogle Scholar
• Pronai L, Ichikawa Y, Ichimori K, Nakazawa H, Arimori S. Association of enchanced superoxide generation by neutrophils with low superoxide scavenging activity of the peripheral blood, joint fluid, and their leukocyte components in rheumatoid arthritis: effects of slow-acting anti-rheumatic drugs and disease activity. Clin Exp Rheumatol 1991; 9: 149–55
   PubMed Web of Science ®Google Scholar
• Biemond P, Swaak A J, Penders J M, Beindorff C M, Koster J F. Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarhtritis: in vivo inhibition by the anti-rheumatic drug piroxicam due to interference with the activation of NADPH-oxidase. Ann Rheum Dis 1986; 45: 249–55
   PubMed Web of Science ®Google Scholar
• Howe C B, Fordham J N, Brown K A, Currey H LF. Polymorphonuclear cell function in rheumatoid arthritis and in Felty's syndrome. Ann Rheum Dis 1981; 40: 370–5
   PubMed Web of Science ®Google Scholar
• Wandall J H. Leucocyte function in patients with rheumatoid arthritis: quantitative in vivo leucocyte mobilisation and in-vitro functions of blood and exudate leucocytes. Ann Rheum Dis 1985; 44: 694–700
   PubMedGoogle Scholar
• Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J F, Cooper N S. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Borregaard N, Heiple J M, Simons E R, Clark R A. Subcellular localization of the b-cytochrome component of the human neutrophil oxidase: translocation during activation. J Cell Biol 1983; 97: 52–61
   PubMed Web of Science ®Google Scholar
• Storgaard M, West J M, Nielsen S L, Obel N. Quantification of neutrophil chemotaxis: A comparison of stereological and 51Cr-labelling methods. Acta Pathol Microbiol Immunol Scand 1995; 103: 185–92
   PubMedGoogle Scholar
• Mege J L, Capo C, Bongrand P, Richard P, Roux H. Monocytes and granulocytes in rheumatoid arthritis (RA): phagocytic activity and superoxide anion production. Clin Rheumatol 1985; 4: 433–40
   PubMedGoogle Scholar
• Chiu P L, Davis P, Wong K, Dasgupta M. Superoxide production in neutrophils of patients with rheumatoid arthritis and Felty's syndrome. J Rheumatol 1983; 10: 694–700
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Ohashi T, Niwa Y. Oxygen radical production by neutrophils from patients with bacterial infection and rheumatoid arthritis. Measurement of hydrogen peroxide may most accurately represent enhancement of oxygen radical production during infection. Inflammation 1986; 10: 119–30
   PubMedGoogle Scholar
• Suryaprabha P, Das U N, Ramesh G, Kumar K V, Kumar G S. Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids 1991; 43: 251–5
   PubMed Web of Science ®Google Scholar
• Sheja A, Forsgren A, Marsal L, Wollenheim F. Inhibition of in vivo leucocyte migration by NSAIDs. Clin Exp Rheumatol 1985; 3: 53–8
   PubMedGoogle Scholar
• Goddard D H, Kirk A P, Kirwan J R, Johnson G D, Holborow E J. Impaired polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 151–6
   PubMedGoogle Scholar
• Hanlon S M, Panayi G S, Laurent R. Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis 1980; 39: 68–74
   PubMed Web of Science ®Google Scholar
• Hilario M O, Goldenberg J, Atra E, Naspitz C K. Chemotaxis of leukocytes from peripheral blood of patients with juvenile rheumatoid arthritis (JRA). Allergol Immunopathol 1990; 18: 243–8
   PubMedGoogle Scholar
• Attai W M, Ah M KH, Abu-Ghazalah L MA, Shams A H, Clark H W, Brown T M, et al. Defective serum chemotactic capacity in rheumatoid arthritis. Ann Allergy 1983; 50: 266–70
   PubMedGoogle Scholar
• Graham G G, Dale M M. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes-II. Evidence for the formation and biological activity of aurocyan-ide. Biochem Pharmacol 1990; 39: 1697–702
   PubMedGoogle Scholar
• Rudkowski R, Graham G G, Champion G D, Ziegler J B. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes-I. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 1687–95
   PubMed Web of Science ®Google Scholar
• Davis P, Johnston C. Effects of gold compounds on function of phagocytic cells. Inflammation 1986; 10: 311–20
   PubMedGoogle Scholar
• Melby K, Quie P G. Effects of methotrexate, ampicillin and gentamicin alone and in combination on the in vitro locomotion on human polymorphonuclear cells (PMN). Acta Pathol Microbiol Immunol Scand 1984; 92: 331–3
   Google Scholar
• Elmgreen J, Ahnfelt-Ronne I, Nielsen O H. Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway. Ann Rheum Dis 1989; 48: 134–8
   PubMedGoogle Scholar
• Kerwar S S, Oronsky A L. Methotrexate in rheumatoid arthritis: studies with animal models. Adv Enzyme Regul 1989; 29: 247–65
   PubMedGoogle Scholar
• Oallaghan J W, Forrest M J, Brooks P M. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int 1988; 8: 41–5
   PubMedGoogle Scholar
• Sperling R I, Coblyn J S, Larkin J K, Al Benincaso, Austen K F, Weinblatt M E. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a singleoral dose of methotrexate. Arthritis Rheum 1990; 33: 1149–55
   PubMedGoogle Scholar
• Porter D R, Capell H A. Sulphasalazine as a disease modifying anti-rheumatic drug. Clin Rheumatol 1990; 4: 535–51
   Google Scholar
• Wandall J H. Effects of sulphasalazine and its metabolites on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Aliment Pharmacol Ther 1991; 5: 609–19
   PubMedGoogle Scholar
• Humbria A, Diaz-Gonzalez F, Campanero M R, Arroyo A G, Laffon A, Gonzalez-Amaro R, Sanchez-Madrid F. Expression of L-selectin, CD43, and CD44 in synovial fluid neutrophils from patients with inflammatory joint diseases. Evidence for a soluble form of L-selectin in synovial fluid. Arthritis Rheum 1994; 37: 342–48
   PubMed Web of Science ®Google Scholar
• Felzmann T, Gadd S, Majdic O, Mauer O, Petera P, Smolen J, et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 1991; 11: 205–12
   PubMed Web of Science ®Google Scholar